Drug intelligence / Profile preview

CG-P5 peptide

Development stage: Phase 1
Lead developer: Caregen
Modality: Peptides
Administration: Ophthalmic

Overview

CG-P5 peptide is a synthetic peptide drug candidate under development by Caregen for the treatment of wet (neovascular/exudative) age-related macular degeneration. It is administered as an ophthalmic eye drop and is currently in Phase 1 clinical trials to evaluate its safety and tolerability in patients with this condition. The precise mechanism of action has not been publicly defined. Caregen specializes in biomimetic peptides and growth factors for various medical and cosmetic applications[1][2][3][4][8].

Other names: CG P5 peptide

Beyond the preview

Go deeper on CG-P5 peptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CG-P5 peptide.

Explore the full profile